A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & Combination Potential
Time: 2:15 pm
day: Conference Day One
Details:
- Presenting preclinical updates on a lead covalent TEADi including in vivo efficacy
- Harnessing TEAD selectivity to expand into TEADi-responsive indications
- Exploring combination approaches with KRASi
